Role of Tumor-Infiltrating B Cells in Clinical Outcome of Patients with Melanoma Treated With Dabrafenib Plus Trametinib.
Jan C BraseRobert F H WalterAlexander SavchenkoDaniel GusenleitnerJames GarrettTobias SchimmingRenata VaraljaiDeborah CastellettiJu KimNaveen DakappagariKen SchultzCaroline RobertGeorgina V LongPaul D NathanAntoni RibasKeith T FlahertyBoguslawa KaraszewskaJacob SchachterAntje SuckerKurt W SchmidLisa ZimmerElisabeth LivingstoneEduard GasalDirk SchadendorfAlexander RoeschPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)
B cells may serve as a potential biomarker to predict clinical outcome in patients with advanced melanoma treated with dabrafenib plus trametinib. As separate studies have shown an opposite effect for B-cell levels and response to immunotherapy, B cells may serve as a potential biomarker to facilitate treatment selection. Further validation in a larger patient cohort is needed.